Patents by Inventor Vaios Karanikas

Vaios Karanikas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES FOR THE TREATMENT OF AML
    Publication number: 20240352136
    Abstract: The present invention relates to anti-CD-25 antibodies for use in the treatment of acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).
    Type: Application
    Filed: September 2, 2022
    Publication date: October 24, 2024
    Inventors: Maria Amann, Laurène Pousse, Christophe Boetsch, Martin Weisser, Theresa Kolben, Vaios Karanikas, Jan Eckmann, Bruno Carneiro de Medeiros
  • NOVEL BIOMARKERS AND USES THEREOF
    Publication number: 20240094212
    Abstract: Disclosed herein are novel biomarkers for identifying patients, with cancer, likely to benefit from treatment with an anti-CD25 agent. Also disclosed are methods using said biomarkers for making a treatment decision—or monitoring treatment with an anti-CD25 agent as well as methods of treating a patient, with cancer, comprising administering an anti-CD25 agent based on prior use of the present biomarkers.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael CANNARILE, Bruno GOMES, Vaios KARANIKAS, Theresa KOLBEN, Dominik RUETTINGER, Fabian SCHMICH
  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 11613587
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
  • COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20210087291
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: August 7, 2020
    Publication date: March 25, 2021
    Inventors: Christian KLEIN, Vaios KARANIKAS, Pablo UMANA, Alfred ZIPPELIUS, Daniela Stefanie THOMMEN, Jens SCHREINER
  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 10781262
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: September 22, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
  • COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS
    Publication number: 20170349666
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Application
    Filed: May 19, 2017
    Publication date: December 7, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Thommen, Jens Schreiner